|
KR101939710B1
(ko)
|
2011-12-21 |
2019-01-17 |
노비라 테라퓨틱스, 인코포레이티드 |
B형 간염의 항바이러스성 제제
|
|
UY34993A
(es)
|
2012-08-28 |
2014-02-28 |
Janssen R & D Ireland |
Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
|
|
WO2014131847A1
(en)
|
2013-02-28 |
2014-09-04 |
Janssen R&D Ireland |
Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
|
|
JP6419155B2
(ja)
|
2013-04-03 |
2018-11-07 |
ヤンセン・サイエンシズ・アイルランド・ユーシー |
Ｎ−フェニル−カルボキサミド誘導体およびｂ型肝炎を治療するための医薬品としてのその使用
|
|
JO3583B1
(ar)
|
2013-05-17 |
2020-07-05 |
Janssen Sciences Ireland Uc |
مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
|
|
HRP20181863T1
(hr)
|
2013-05-17 |
2018-12-28 |
Janssen Sciences Ireland Uc |
Derivati sulfamoiltiofenamida i njihova uporaba kao lijekova za liječenje hepatitisa b
|
|
NO3024819T3
(enExample)
|
2013-07-25 |
2018-07-21 |
|
|
|
MX368158B
(es)
|
2013-10-23 |
2019-09-20 |
Janssen Sciences Ireland Uc |
Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
|
|
HK1223094A1
(zh)
|
2013-11-14 |
2017-07-21 |
Novira Therapeutics Inc. |
氮杂环庚烷衍生物和治疗乙型肝炎感染的方法
|
|
US9169212B2
(en)
|
2014-01-16 |
2015-10-27 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
|
US10392349B2
(en)
|
2014-01-16 |
2019-08-27 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
|
WO2015120178A1
(en)
|
2014-02-05 |
2015-08-13 |
Novira Therapeutics, Inc. |
Combination therapy for treatment of hbv infections
|
|
DK3102572T3
(en)
|
2014-02-06 |
2019-02-04 |
Janssen Sciences Ireland Uc |
SULFAMOYLPYRROLAMIDE DERIVATIVES AND THEIR USE AS MEDICINES TO TREAT HEPATITIS B
|
|
HK1247147A1
(zh)
|
2015-03-19 |
2018-09-21 |
诺维拉治疗公司 |
氮杂环辛烷和氮杂环壬烷衍生物以及治疗乙型肝炎感染的方法
|
|
US10875876B2
(en)
|
2015-07-02 |
2020-12-29 |
Janssen Sciences Ireland Uc |
Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
|
|
CN108430971A
(zh)
|
2015-09-29 |
2018-08-21 |
诺维拉治疗公司 |
乙型肝炎抗病毒剂的晶体形式
|
|
KR20180129943A
(ko)
|
2016-04-15 |
2018-12-05 |
노비라 테라퓨틱스, 인코포레이티드 |
캡시드 조립 억제제를 포함하는 배합물 및 방법
|
|
EP4483875A3
(en)
|
2016-05-10 |
2025-04-02 |
C4 Therapeutics, Inc. |
Spirocyclic degronimers for target protein degradation
|
|
CN109641874A
(zh)
|
2016-05-10 |
2019-04-16 |
C4医药公司 |
用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
|
|
CN109562107A
(zh)
|
2016-05-10 |
2019-04-02 |
C4医药公司 |
用于靶蛋白降解的杂环降解决定子体
|
|
EP3455219A4
(en)
|
2016-05-10 |
2019-12-18 |
C4 Therapeutics, Inc. |
AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
|
|
MX2018014377A
(es)
|
2016-05-27 |
2019-03-14 |
Gilead Sciences Inc |
Metodos para tratar infecciones por virus de hepatitis b usando inhibidores de proteina no estructural 5a (ns5a), proteina no estructural 5b (ns5b) o proteina no estructural 3 (ns3).
|
|
CA3029566A1
(en)
*
|
2016-06-29 |
2018-01-04 |
Novira Therapeutics, Inc. |
Diazepinone derivatives and their use in the treatment of hepatitis b infections
|
|
AU2017286890B2
(en)
*
|
2016-06-29 |
2021-09-09 |
Novira Therapeutics, Inc. |
Oxadiazepinone derivatives and their use in the treatment of hepatitis B infections
|
|
EP3484885B1
(en)
*
|
2016-07-14 |
2020-03-04 |
H. Hoffnabb-La Roche Ag |
Carboxy 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases
|
|
JOP20190024A1
(ar)
|
2016-08-26 |
2019-02-19 |
Gilead Sciences Inc |
مركبات بيروليزين بها استبدال واستخداماتها
|
|
WO2018045150A1
(en)
|
2016-09-02 |
2018-03-08 |
Gilead Sciences, Inc. |
4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
|
|
MA46093A
(fr)
|
2016-09-02 |
2021-05-19 |
Gilead Sciences Inc |
Composés modulateurs du recepteur de type toll
|
|
CN109790123B
(zh)
*
|
2016-09-18 |
2021-06-25 |
正大天晴药业集团股份有限公司 |
新型衣壳蛋白装配抑制剂
|
|
FI3526323T3
(fi)
|
2016-10-14 |
2023-06-06 |
Prec Biosciences Inc |
Hepatiitti B -viruksen genomissa oleville tunnistussekvensseille spesifisiä muokattuja meganukleaaseja
|
|
CN116751200A
(zh)
|
2016-11-07 |
2023-09-15 |
爱彼特生物制药公司 |
含有取代的吡啶酮的三环化合物以及使用其的方法
|
|
AR110768A1
(es)
|
2017-01-31 |
2019-05-02 |
Gilead Sciences Inc |
Formas cristalinas de tenofovir alafenamida
|
|
LT3587420T
(lt)
|
2017-02-23 |
2021-07-12 |
Fujian Cosunter Pharmaceutical Co., Ltd. |
Triciklis junginys ir jo naudojimas
|
|
US11098010B2
(en)
|
2017-03-21 |
2021-08-24 |
Arbutus Biopharma Corporation |
Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
|
|
BR102018007822A2
(pt)
|
2017-04-20 |
2018-11-06 |
Gilead Sciences, Inc. |
composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
|
|
WO2018227427A1
(en)
|
2017-06-14 |
2018-12-20 |
Bayer Aktiengesellschaft |
Substituted bridged diazepane derivatives and use thereof
|
|
EP3641762B1
(en)
|
2017-06-20 |
2026-02-18 |
C4 Therapeutics, Inc. |
N/o-linked degrons and degronimers for protein degradation
|
|
GB201716871D0
(en)
*
|
2017-10-13 |
2017-11-29 |
Inst Of Cancer Research: Royal Cancer Hospital |
Compounds
|
|
BR112020008765A2
(pt)
|
2017-11-02 |
2020-10-20 |
Aicuris Gmbh & Co. Kg |
indol-2-carboxamidas pirazolo-piperidina substituídas altamente ativas inovadoras ativas contra o vírus da hepatite b (hbv)
|
|
GEAP202115351A
(en)
|
2017-11-02 |
2021-12-10 |
Aicuris Gmbh & Co Kg |
Novel, highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
|
|
KR102492187B1
(ko)
|
2017-12-20 |
2023-01-27 |
인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. |
Sting 어댑터 단백질을 활성화하는 포스포네이트 결합을 가진 3'3' 사이클릭 다이뉴클레오티드
|
|
JP7098748B2
(ja)
|
2017-12-20 |
2022-07-11 |
インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． |
Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する２’３’環状ジヌクレオチド
|
|
EA038176B9
(ru)
*
|
2018-01-04 |
2021-09-07 |
Фуцзянь Косантер Фармасьютикал Ко., Лтд. |
Производные пирроло-[1,2,5]бензотиадиазепина и их применение для лечения заболевания, вызванного вирусом гепатита в
|
|
KR102708681B1
(ko)
|
2018-02-13 |
2024-09-26 |
길리애드 사이언시즈, 인코포레이티드 |
Pd-1/pd-l1 억제제
|
|
KR102526964B1
(ko)
|
2018-02-26 |
2023-04-28 |
길리애드 사이언시즈, 인코포레이티드 |
Hbv 복제 억제제로서의 치환된 피롤리진 화합물
|
|
JP2021515769A
(ja)
|
2018-03-14 |
2021-06-24 |
ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー |
カプシド集合調節剤の投薬レジメン
|
|
US10870691B2
(en)
|
2018-04-05 |
2020-12-22 |
Gilead Sciences, Inc. |
Antibodies and fragments thereof that bind hepatitis B virus protein X
|
|
TWI818007B
(zh)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
|
TWI833744B
(zh)
|
2018-04-06 |
2024-03-01 |
捷克科學院有機化學與生物化學研究所 |
3'3'-環二核苷酸
|
|
TW202005654A
(zh)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
２，２，─環二核苷酸
|
|
TW201945388A
(zh)
|
2018-04-12 |
2019-12-01 |
美商精密生物科學公司 |
對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
|
|
EP4600247A3
(en)
|
2018-04-19 |
2025-11-19 |
Gilead Sciences, Inc. |
Pd-1/pd-l1 inhibitors
|
|
US20190359645A1
(en)
|
2018-05-03 |
2019-11-28 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
|
|
UA126421C2
(uk)
|
2018-07-13 |
2022-09-28 |
Гіліад Сайєнсіз, Інк. |
Інгібітори pd-1/pd-l1
|
|
TWI826492B
(zh)
|
2018-07-27 |
2023-12-21 |
加拿大商愛彼特生物製藥公司 |
經取代四氫環戊[c]吡咯、經取代二氫吡咯，其類似物及使用其之方法
|
|
WO2020028097A1
(en)
|
2018-08-01 |
2020-02-06 |
Gilead Sciences, Inc. |
Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
|
|
US11560370B1
(en)
*
|
2018-10-22 |
2023-01-24 |
Assembly Biosciences, Inc. |
5-membered heteroaryl carboxamide compounds for treatment of HBV
|
|
US11236085B2
(en)
|
2018-10-24 |
2022-02-01 |
Gilead Sciences, Inc. |
PD-1/PD-L1 inhibitors
|
|
WO2020092528A1
(en)
|
2018-10-31 |
2020-05-07 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
|
|
PE20211655A1
(es)
|
2018-10-31 |
2021-08-24 |
Gilead Sciences Inc |
Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1
|
|
PY1991601A
(es)
|
2018-11-02 |
2020-11-02 |
Aicuris Gmbh & Co Kg |
Nuevas 6,7-dihidro-4h-pirazolo [1,5-a] pirazina indole-2-carboxamidas activas contra el virus de la hepatitis b (vhb)
|
|
PY1991606A
(es)
|
2018-11-02 |
2022-02-10 |
Aicuris Gmbh & Co Kg |
Nueva urea 6,7-dihidro-4h-pirazolo [4,3-c] piridinas activas contra el virus de la hepatitis b (vhb)
|
|
PY1991608A
(es)
|
2018-11-02 |
2022-02-10 |
Aicuris Gmbh & Co Kg |
Nueva urea 6,7-dihidro-4h-pirazolo [1,5-a] pirazina activas contra el virus de la hepatitis b (vhb)
|
|
PY1991611A
(es)
|
2018-11-02 |
2022-03-14 |
Aicuris Gmbh & Co Kg |
Nueva urea 6,7-dihidro-4h-pirazolo [1,5-a] pirazinas activas contra el virus de la hepatitis b (vhb)
|
|
TW202031666A
(zh)
|
2018-11-02 |
2020-09-01 |
德商艾庫瑞斯公司 |
對抗b型肝炎病毒(hbv)之新穎6,7-二氫-4h-噻唑并[5,4-c]吡啶脲活性劑
|
|
UY38436A
(es)
|
2018-11-02 |
2020-05-29 |
Aicuris Gmbh & Co Kg |
Nuevas 6,7-dihidro-4h-pirazolo[1,5-a] pirazinindol-2-carboxamidas activas contra el virus de la hepatitis b (vhb)
|
|
TW202415643A
(zh)
|
2018-12-12 |
2024-04-16 |
加拿大商愛彼特生物製藥公司 |
經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
|
|
CN120698983A
(zh)
|
2018-12-20 |
2025-09-26 |
C4医药公司 |
靶向蛋白降解
|
|
US11096931B2
(en)
|
2019-02-22 |
2021-08-24 |
Janssen Sciences Ireland Unlimited Company |
Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
|
|
WO2020178768A1
(en)
|
2019-03-07 |
2020-09-10 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
|
CN113543851B
(zh)
|
2019-03-07 |
2025-03-18 |
捷克共和国有机化学与生物化学研究所 |
2’3’-环二核苷酸及其前药
|
|
WO2020178770A1
(en)
|
2019-03-07 |
2020-09-10 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotides and prodrugs thereof
|
|
TW202212339A
(zh)
|
2019-04-17 |
2022-04-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
TW202210480A
(zh)
|
2019-04-17 |
2022-03-16 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
CN113748113A
(zh)
|
2019-04-30 |
2021-12-03 |
艾库里斯有限及两合公司 |
具有抗乙型肝炎病毒(hbv)活性的新型吲哚嗪-2-甲酰胺类化合物
|
|
WO2020221826A1
(en)
|
2019-04-30 |
2020-11-05 |
Aicuris Gmbh & Co. Kg |
Novel indole-2-carboxamides active against the hepatitis b virus (hbv)
|
|
EP3962912A1
(en)
|
2019-04-30 |
2022-03-09 |
AiCuris GmbH & Co. KG |
Novel phenyl and pyridyl ureas active against the hepatitis b virus (hbv)
|
|
CU20210090A7
(es)
|
2019-04-30 |
2022-06-06 |
Aicuris Gmbh & Co Kg |
Compuestos derivados de oxalil piperazinas activos contra el virus de la hepatitis b (vhb)
|
|
US11491148B2
(en)
|
2019-05-06 |
2022-11-08 |
Janssen Sciences Ireland Unlimited Company |
Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
|
|
TWI826690B
(zh)
|
2019-05-23 |
2023-12-21 |
美商基利科學股份有限公司 |
經取代之烯吲哚酮化物及其用途
|
|
AU2020301161B2
(en)
|
2019-06-25 |
2023-10-26 |
Gilead Sciences, Inc. |
FLT3L-Fc fusion proteins and methods of use
|
|
WO2021011891A1
(en)
|
2019-07-18 |
2021-01-21 |
Gilead Sciences, Inc. |
Long-acting formulations of tenofovir alafenamide
|
|
WO2021034804A1
(en)
|
2019-08-19 |
2021-02-25 |
Gilead Sciences, Inc. |
Pharmaceutical formulations of tenofovir alafenamide
|
|
EP4458975A3
(en)
|
2019-09-30 |
2025-02-12 |
Gilead Sciences, Inc. |
Hbv vaccines and methods treating hbv
|
|
ES3022990T3
(en)
|
2019-12-06 |
2025-05-29 |
Prec Biosciences Inc |
Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
|
|
CA3169348A1
(en)
|
2020-03-20 |
2021-09-23 |
Gilead Sciences, Inc. |
Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
|
|
US20210371388A1
(en)
*
|
2020-05-12 |
2021-12-02 |
Baruch S. Blumberg Institute |
Bicyclic Carboxamide with Exocyclic Urea Derivatives as Antivirals for the Treatment of HBV Infection
|
|
JP7706475B2
(ja)
|
2020-05-15 |
2025-07-11 |
福建▲広▼生中霖生物科技有限公司 |
三環式化合物を含む組み合わせ及びｈｂｖ治療薬物の製造におけるその使用
|
|
ES3054072T3
(en)
|
2020-08-07 |
2026-01-29 |
Gilead Sciences Inc |
Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
|
|
TW202406932A
(zh)
|
2020-10-22 |
2024-02-16 |
美商基利科學股份有限公司 |
介白素2-Fc融合蛋白及使用方法
|
|
AU2022274607A1
(en)
|
2021-05-13 |
2023-11-16 |
Gilead Sciences, Inc. |
COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
|
|
WO2022271650A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
US11932634B2
(en)
|
2021-06-23 |
2024-03-19 |
Gilead Sciences, Inc. |
Diacylglycerol kinase modulating compounds
|
|
WO2022271659A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
EP4359415A1
(en)
|
2021-06-23 |
2024-05-01 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
WO2025240243A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus
|
|
WO2025240242A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with ribavirin
|
|
WO2025240244A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection
|
|
WO2025240246A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with ribavirin
|